+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lung Cancer Therapeutics: Global Markets

  • ID: 4668824
  • Report
  • November 2018
  • Region: Global
  • 161 Pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Astellas Pharma Inc.
  • Bayer Ag
  • Boehringer Ingelheim Gmbh
  • Celgene Corp.
  • Eli Lilly And Co.
  • MORE

Report Scope:

This report provides a detailed analysis of prevailing lung cancer treatment guidelines in different geographic regions. This report looks at lung cancer therapeutics market revenue by disease type (i.e., NSCLC and SCLC) and the proportion of chemotherapeutics and targeted therapies used for treating each disease type in different geographic regions. Non-pharmaceutical treatment segments like radiation and surgery are excluded from this report. Lung cancer therapeutic market data is present for 2017 and for the forecast period, which is 2018 to 2023. The market data provided in this report are based on manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Detailed lung cancer therapeutic market analyses are presented for five regions: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

Global market drivers, trends and challenges affecting the lung cancer therapeutics market are presented in this report. Detailed analyses of the competitive environments, pipeline analysis, patents, regulatory landscape and reimbursement landscape are included in the report.

The Report Includes:

  • 34 data tables and 32 additional tables
  • An in-depth overview of the global market for lung cancer therapeutics within the industry
  • Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Identification of key market dynamics, trends, opportunities and factors influencing the global lung cancer drug technology
  • Assessment of major regulatory pathways and hurdles faced by lung cancer therapeutic product manufacturers
  • Information pertaining to lung cancer drug patent applications, expirations and the latest key technology developments, pipeline analysis, reimbursement scenarios, and unmet needs associated with the market
  • Dossier of mergers and acquisitions, new product development, strategies, research and development activities of major market players
  • Examination of the competitive landscape for the lung cancer therapeutics market, and information pertaining to leading lung cancer market players, their marketed products, pipeline products and product patent expirations
  • Detailed company profiles of major manufacturers of oncology products, including Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Novartis International AG and Pfizer Inc.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Astellas Pharma Inc.
  • Bayer Ag
  • Boehringer Ingelheim Gmbh
  • Celgene Corp.
  • Eli Lilly And Co.
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Introduction
  • Lung Cancer Types
  • In Situ Lung Cancer
  • Malignant Lung Tumors
  • Stages of Lung Cancer
  • Staging of NSCLC
  • Staging of SCLC
  • Risk Factors
  • Tobacco Smoking
  • Second-Hand Smoking (SHS)
  • Exposure to Asbestos
  • Exposure to Other Elements
  • Family History
  • Personal History
  • Lung Cancer Symptoms
  • Symptoms of Tumor Growth in the Lungs and Chest
  • Symptoms Caused by Metastases Beyond the Chest
  • Symptoms Caused by Tumor Secretion
  • Lung Cancer Diagnosis
  • General Screening Tests
  • Lung Cancer Management
  • Radiation Therapy
  • Chemotherapy
  • Surgery
  • Targeted Therapy for Lung Cancer
  • Immunotherapy for Lung Cancer
  • Palliative Treatment for Lung Cancer

Chapter 4 Market Dynamics

  • Market Drivers
  • Global Increase in Lung Cancer Incidence
  • Increase in Healthcare Expenditures and Government Funding in Key Countries
  • Robust Clinical Drug Pipeline
  • Increasing Life Expectancy of Lung Cancer Patients
  • Surge in Female Smokers
  • Market Restraints
  • Patent Expiration of Key Drug Molecules
  • Regulatory and Reimbursement Hurdles
  • Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
  • Market Opportunities
  • Highest Incidence of Lung Cancer in Asia-Pacific
  • Increasing Demand for Targeted Therapies (EGFR or ALK Inhibitors, TKIs)
  • Increasing Incidence of NSCLC and its Non-responsiveness to Chemotherapy
  • Increasing Lung Cancer Incidence Among Non-Smokers
  • Clinical Trial Failures

Chapter 5 Market Breakdown by Lung Cancer Type

  • Market Overview
  • Market Size and Forecast
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

Chapter 6 Market Breakdown by Region

  • Epidemiology of Lung Cancer
  • Global Market for Lung Cancer Therapeutics by Region
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America

Chapter 7 Reimbursement Landscape

  • Introduction
  • United States
  • Lung Cancer Drug Reimbursement
  • Germany
  • Lung Cancer Drug Reimbursement
  • Brazil
  • China

Chapter 8 Patent Review

  • Patents Granted
  • Patent Expiration

Chapter 9 Regulatory Landscape

  • Regulatory Challenges for Lung Cancer Therapeutics
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Mutual Recognition Procedure
  • Decentralized Procedure
  • Centralized Procedure
  • Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • South America
  • Brazil
  • Argentina

Chapter 10 Competitive Landscape

  • Major Lung Cancer Drug Companies
  • Eli Lilly and Co.
  • AstraZeneca Pharmaceuticals
  • Pfizer Inc.

Chapter 11 Pipeline Analysis

  • Introduction
  • Late-Stage Pipeline Drug Candidates
  • JAK Inhibitors for Lung Cancer
  • Third-Generation EGFR TKIs

Chapter 12 Company Profiles

  • ABBVIE INC.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • AMGEN INC.
  • Company Overview
  • ASTELLAS PHARMA INC.
  • Financials
  • ASTRAZENECA PLC
  • Company Overview
  • Financials
  • Products and Services
  • Developments and Strategies
  • BAYER AG
  • Company Overview
  • Financials
  • Product Information
  • BETA PHARMA INC.
  • Business Overview
  • Products and Services
  • BOEHRINGER INGELHEIM GMBH
  • Company Overview
  • Financials
  • Products and Services
  • Development and Strategies
  • BRISTOL-MYERS SQUIBB CO.
  • Company Overview
  • Financials
  • Products and Services
  • CELGENE CORP.
  • Company Overview
  • Financials
  • Products and Services
  • DAIICHI SANKYO CO., LTD.
  • Company Overview
  • Financials
  • Product and Services
  • ELI LILLY AND CO.
  • Company Overview
  • Financials
  • F. HOFFMANN-LA ROCHE AG
  • Company Overview
  • Financials
  • Products and Services
  • MERCK & CO., INC.
  • Company Overview
  • Financials
  • Products and Services
  • Development and Strategies
  • NOVARTIS INTERNATIONAL AG
  • Company Overview
  • Financials
  • Products and Services
  • Development and Strategies
  • PFIZER INC.
  • Company Overview
  • Financials
  • Product Information
  • Development and Strategies
  • TAKEDA PHARMACEUTICALS CO.
  • Company Overview

Chapter 13 Appendix: Acronyms

List of Tables
Summary Table: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 1: TNM Classification of Malignant Tumors of Lung Cancer
Table 2: Five-Year Survival Rates, NSCLC and SCLC
Table 3: Targeted Therapy for Lung Cancer
Table 4: Targeted Antibodies Used in Lung Cancer
Table 5: Immunomodulators Used in Lung Cancer
Table 6: CAR T-Cell Therapy Clinical Trials Under Investigation
Table 7: Comparison of Overall Estimated Number of New Cancer Cases, by Type, 2018
Table 8: Age-Standardized Lung Cancer Incidence Rate, Rankings by Country, 2017
Table 9: Age-Standardized Lung Cancer Incidence Rate in Men, Rankings by Country, 2017
Table 10: Age-Standardized Lung Cancer Incidence Rate in Women, Ranking by Country, 2017
Table 11: Lung Cancer Incidence in Key Countries, 2017
Table 12: Proportion of Daily Cigarette Smokers in Europe, by Gender, 2014
Table 13: Patent Expiration of Lung Cancer Drugs
Table 14: Incidence of Lung Cancer in Asia-Pacific, 2016
Table 15: Prominent Drugs to Treat Lung Cancer
Table 16: Global Market for Lung Cancer Therapeutics, by Type, Through 2023
Table 17: Global Market for Lung Cancer Therapeutics, by Region, Through 2023
Table 18: Estimated Lung Cancer Statistics for Canada, 2017
Table 19: Lung Cancer Incidence in Canada, Male and Female
Table 20: Overall Healthcare Expenditures in Europe, by Country, Through 2015
Table 21: Number of New Lung Cancer Cases in the U.K., by Gender, 2015
Table 22: Medicare Part B: Lung Cancer Drug Payment Limits, 2018
Table 23: Lung Cancer Drug Reimbursement in Germany, 2018
Table 24: Oncology Drugs Covered by China's National Insurance
Table 25: U.S. Patents on Lung Cancer Therapeutics, 2001-2018
Table 26: Patent Expiration of Lung Cancer Drugs
Table 27: List of FDA-Approved Drugs, Through 2018
Table 28: Lung Cancer Drugs Approved by Health Canada, Through 2018
Table 29: NSCLC Drugs Authorized by the EMA, Through 2018
Table 30: NSCLC Drugs Pending Approval by the EMA, Through 2018
Table 31: NSCLC Drugs Withdrawn by the EMA, Through 2018
Table 32: NSCLC Drugs Pending Application Withdrawal by the EMA, Through 2018
Table 33: SCLC Drugs Pending Withdrawal by the EMA, Through 2018
Table 34: Global Ranking of Lung Cancer Drug Companies, 2017
Table 35: Eli Lilly and Co.: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 36: AstraZeneca Pharmaceuticals: Lung Cancer Marketed Products and Investigational Molecules, Through 2018
Table 37: Lung Cancer Pipeline Drugs, Through 2018
Table 38: Clinical Efficacy of Select Third-Generation EGFR TKIs in Clinical Development
Table 39: AbbVie Inc.: Net Revenue, 2015-2017
Table 40: AbbVie Inc.: Lung Cancer Pipeline
Table 41: Astellas Pharma Inc.: Net Revenue, 2013-2017
Table 42: Astellas Pharma Inc.: Net Revenue, by Country/Region, 2014-2017
Table 43: AstraZeneca Plc: Net Revenue, 2014-2017
Table 44: AstraZeneca Plc: Marketed Products, 2018
Table 45: Bayer AG: Net Revenue, 2015-2017
Table 46: Bayer AG: Lung Cancer Pipeline Molecules
Table 47: Boehringer Ingelheim GmbH: Net Revenue, 2014-2016
Table 48: Boehringer Ingelheim GmbH: Marketed Product, 2018
Table 49: Bristol-Myers Squibb: Net Revenue, 2014-2016
Table 50: Bristol-Myers Squibb: Marketed Products, 2018
Table 51: Celgene Corp.: Net Revenue, 2015-2016
Table 52: Daiichi Sankyo Co., Ltd.: Net Revenue, 2015-2017
Table 53: Eli Lilly and Co.: Net Revenue, 2014-2017
Table 54: Eli Lilly and Co.: Net Revenue, by Segment, 2014-2016
Table 55: Eli Lilly and Co.: Net Revenue, by Oncology Drug, 2014-2016
Table 56: F. Hoffmann-La Roche Ltd.: Net Revenue, by Segment, Through 2017
Table 57: Tarceva: Drug Revenue, by Country/Region, 2016-2017
Table 58: Merck & Co., Inc.: Net Revenue, 2014-2016
Table 59: Novartis International AG: Net Revenue, by Segment, Through 2017
Table 60: Novartis International AG: Oncology Drugs Revenue, 2015-2017
Table 61: Pfizer Inc.: Net Revenue, 2014-2017
Table 62: Pfizer Inc.: Oncology Drug Revenue, 2015-2017
Table 63: Pfizer Inc.: Oncology Drugs Revenue, 2015-2017
Table 64: Pfizer Inc.: Lung Cancer Marketed Products and Investigational Drug Candidates, 2018
Table 65: Acronyms Used in Global Lung Cancer Therapeutics Market

List of Figures
Summary Figure: Global Market for Lung Cancer Therapeutics, by Type, 2017-2023
Figure 1: Gross Anatomy of the Human Lung
Figure 2: Share of Lung Cancer Types, by Histology
Figure 3: National Cancer Institute Research Funding, 2011-2016
Figure 4: U.S. Smoking Statistics, by Gender, 2017
Figure 5: Percentage Share of Lung Cancer Incidence, by Type of Mutation
Figure 6: Global Market for Non-Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 7: Global Market for Small Cell Lung Cancer Therapeutics, 2017-2023
Figure 8: Percentage Share of Global Lung Cancer Incidence, by Country/Region, 2018
Figure 9: North American Market for Lung Cancer Therapeutics, 2017-2023
Figure 10: Percentage Share of Estimated Cancer Incidence in North America, by Type, 2018
Figure 11: Percentage Share of Estimated Cancer Incidence in the United States, by Type, 2018
Figure 12: European Market for Lung Cancer Therapeutics, 2017-2023
Figure 13: Per Capita Spending on Market Sectors in Europe, 2015
Figure 14: Incidence Rates of Lung Cancer in the U.K., by Gender, 1993-2015
Figure 15: Incidence of Lung Cancer in Scotland, by Cancer Stage, 2014-2015
Figure 16: Incidence of Lung Cancer in Italy, by Gender, 2010 and 2015
Figure 17: Percentage Share of Estimated Cancer Incidence in France, by Type, 2018
Figure 18: Percentage Share of Estimated Cancer Incidence in Germany, by Type, 2018
Figure 19: Asia-Pacific Market for Lung Cancer Therapeutics, 2017-2023
Figure 20: Percentage Share of Estimated Cancer Incidence in Asia-Pacific, by Type, 2018
Figure 21: Estimated Cancer Incidence in Asia-Pacific, by Country, 2018
Figure 22: Middle East and African Market for Lung Cancer Therapeutics, 2017-2023
Figure 23: Percentage Share of Estimated Cancer Incidence in Africa, by Type, 2018
Figure 24: South American Market for Lung Cancer Therapeutics, 2017-2023
Figure 25: Percentage Share of Estimated Cancer Incidence in South America, by Type, 2018
Figure 26: Drug Reimbursement Scenerio in Germany
Figure 27: Federal and Inter-Provincial Approval System for Cancer Drugs in Canada
Figure 28: Medical Device PMDA Approval Procedure
Figure 29: AbbVie Inc.: Revenue Share, by Region, 2016
Figure 30: Erlotinib: Revenue, 2015-2016
Figure 31: AstraZeneca Plc: Financial Performance, 2015-2017
Figure 32: AstraZeneca Plc: Financial Performance, 2013-2017
Figure 33: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 34: AstraZeneca Plc: Revenue Share, by Country/Region, 2017
Figure 35: Bayer AG: Revenue Share, by Region, 2017
Figure 36: Bayer AG: Revenue Share, by Region, 2017
Figure 37: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2016
Figure 38: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2016
Figure 39: Boehringer Ingelheim GmbH: Research and Development Expenditures, 2014-2016
Figure 40: Bristol-Myers Squibb: Revenue Share, by Country/Region, 2016
Figure 41: Bristol-Myers Squibb: Revenue Share, by Business Segment, 2016
Figure 42: Abraxane: Revenue, 2015-2017
Figure 43: Daiichi Sankyo Co., Ltd.: Revenue Share, by Business Segment, 2016
Figure 44: Eli Lilly and Co.: Revenue Share, by Country/Region, 2016
Figure 45: F. Hoffmann-La Roche Ltd.: Pharmaceuticals Revenue Share, by Business Segment, 2016
Figure 46: F. Hoffmann-La Roche Ltd.: Lung Cancer Drug Revenue, 2016-2017
Figure 47: Merck & Co., Inc.: Revenue Share, by Business Segment, 2016
Figure 48: Merck & Co., Inc.: Keytruda Revenue, 2015-2017
Figure 49: Merck & Co., Inc.: Revenue Share, by Region, 2016
Figure 50: Pfizer Inc.: Revenue Share, by Region, 2016
Figure 51: Pfizer Inc.: Revenue Share, by Business Segment, 2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Astellas Pharma Inc.
  • Bayer Ag
  • Boehringer Ingelheim Gmbh
  • Celgene Corp.
  • Eli Lilly And Co.
  • MORE

Grant of fast-track designation to advance therapies by the U.S. FDA, European Medicines Agency, CFDA (China) and MHLW (Japan) is expected to significantly contribute to the overall growth of the lung cancer therapeutics market. The global rise in lung cancer incidence, improving survival rates, rising tobacco use and environmental pollution, along with an increase in the prescription volume of branded therapies in countries such as China, are the major market drivers.

The lung cancer therapeutics market is expected to grow significantly during the forecast period, mainly due to an increase in the number of new lung cancer cases. Lung cancer incidence in the non-smoking group is steadily increasing, mainly due to an increased exposure to carcinogens such as radon, asbestos, and exposure to radioactive elements. This increase in non-smoking lung cancer cases is expected to have a positive impact on the overall lung cancer therapeutic market during the study period.

Reasons for Doing This Study

There have been significant developments in understanding complex molecular and cellular mechanisms involved in lung cancer. As the incidence of lung cancer is increasing in regions such as Asia-Pacific and Europe, government agencies and research firms have shifted their focus on developing new treatment options to improve the lifespan of terminally ill patients. Increased use of targeted therapies and immunotherapies are proving to be beneficial to lung cancer patients. Several advanced therapies for lung cancer are likely to reach the market in the next five years. Due to increased healthcare expenditures on early screening and disease detection, lung cancer therapy market dynamics are expected to change during the forecast period. This study looks at different classes of available drug types and their applications. This report also identifies potential pipeline molecules, which could translate into clinical practice during the forecast period.

This study highlights how the pharmaceutical sector is rapidly changing by forming new paradigms and employing marketing strategies that increase market share. The research provides information on leading market competitors, their market share, partnerships, collaborations, and mergers and acquisitions between pharmaceutical companies.

Note: Product cover images may vary from those shown
5 of 5
  • Abbvie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Beta Pharma Inc.
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly And Co.
  • F. Hoffmann-La Roche Ag
  • Merck & Co., Inc.
  • Novartis International Ag
  • Pfizer Inc.
  • Takeda Pharmaceuticals Co.
Note: Product cover images may vary from those shown
Adroll
adroll